Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.

Jun ZhouYongkun SunWen ZhangJiajia YuanZhi PengWei WangJifang GongLin YangYanshuo CaoHong ZhaoChao ChenWeifeng WangLin ShenAiping Zhou

Published in: Hepatology (Baltimore, Md.) (2022)

Anlotinib combined with TQB2450 showed promising efficacy and was well tolerated in advanced BTCs. KRAS mutation and high TMB might serve as predictors of treatment efficacy.

Keyphrases

squamous cell carcinoma
squamous cell
wild type
smoking cessation